How are New Drug Experiments Showing Promising Traits in Reverse...
pharmatechoutlook

How are New Drug Experiments Showing Promising Traits in Reverse Broader Aging?

By Pharma Tech Outlook | Thursday, February 20, 2020

Researchers are showing how some drugs slow down aging in healthy older mice while blocking the damage to brain cells, which generally occurs in aging and restoring the levels of specific molecules to the ones seen in younger brains.

FREMONT, CA: According to research published in the journal eLife, states that the mouse models of Alzheimer’s disease, the investigational drug candidates can improve memory and slow down the degeneration of brain cells. They can also prove to be useful for treating a broader array of conditions.  It also opens a new pathway that links normal aging to Alzheimer’s disease.  Old age is the most significant risk factor in terms of Alzheimer’s disease. People above the age of 65 years are more prone to developing the disease, and it doubles every five years. Yet, at a molecular level, scientists are not sure about what occurs in the brain with aging that contributes to the disease.

Initially, CMS121 and J147, variants of plant compounds, were developed with medical properties. These compounds were tested positive for the ability to maintain the life of the neurons when unshielded to cellular forms of stress related to aging and Alzheimer’s disease. The researchers have used these drug candidates to treat Alzheimer’s in animal models of the disease. But according to the experiments, they bring to light how the compounds work suggested that they were targeting molecular pathways, which are also known to be vital in longevity and aging.

Check out: Top Long-term Care Solution Companies

In this new research, a strain of mice was given CMS121 or J147 beginning at nine months old, which is equal to late middle age in humans. The team, after four months, tested the memory and behavior of the animals and studied genetic and molecular markers in their brains. The animal that was given the drug performed better on memory tests compared to the ones who did not receive any treatment, but the brains showed differences at the molecule ad cellular levels.

The researchers are planning future experiments to test the effects of CMS1212 and J147 on how other organs are aging. They are also looking forward to using new results to inform the development of new Alzheimer’s drugs, which targets other molecules in the acetyl-coA pathway, which might help in treating the disease.

See Also: Top Pharmacovigilance Consulting/Services Companies

Weekly Brief

Top 10 Analytics Consulting/Services Companies - 2020
Top 10 Analytics Solution Companies - 2020

Read Also